Julie Krop

CIK: 0001643127

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (16.7%)

Position reduction

Option Exercises (M)1 (16.7%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

AQST

Aquestive Therapeutics, Inc.

Director

DMAC

DiaMedica Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

AQST
Aquestive Therapeutics, Inc.
Jun 23, 2026
Exercise(M)
Direct
25K shares at avg. $0.71$18K
AQST
Aquestive Therapeutics, Inc.
Jun 23, 2026
Sale(S)
Direct
25K shares at avg. $5.02$125K
AQST
Aquestive Therapeutics, Inc.
Jun 10, 2026
Award(A)
Stock Option (Right to Purchase)
Direct
50.5K shares-
DMAC
DiaMedica Therapeutics Inc.
Jun 1, 2026
Award(A)
Stock Option (right to buy)
Direct
67.5K shares-
DMAC
DiaMedica Therapeutics Inc.
Aug 11, 2025
Award(A)
Stock Option (right to buy)
Direct
450K shares-
AQST
Aquestive Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock Option (Right to Purchase)
Direct
42K shares at avg. $3.41-

		Type	Shares	Price		Ownership
Jun 23, 2026	AQST Aquestive Therapeutics, Inc.	Exercise(M)	25,000	$0.71	$17,830	Direct
Jun 23, 2026	AQST Aquestive Therapeutics, Inc.	Sale(S)	25,000	$5.02	$125,393	Direct
Jun 10, 2026	AQST Aquestive Therapeutics, Inc.	Award(A) Stock Option (Right to Purchase)	50,500	-	-	Direct
Jun 1, 2026	DMAC DiaMedica Therapeutics Inc.	Award(A) Stock Option (right to buy)	67,500	-	-	Direct
Aug 11, 2025	DMAC DiaMedica Therapeutics Inc.	Award(A) Stock Option (right to buy)	450,000	-	-	Direct
Jun 11, 2025	AQST Aquestive Therapeutics, Inc.	Award(A) Stock Option (Right to Purchase)	42,000	$3.41	-	Direct

1-6 of 6 transactions

About Krop Julie

Krop Julie (SEC CIK 0001643127) files insider reports with the SEC as Director of Aquestive Therapeutics, Inc. (AQST) and Chief Medical Officer of DiaMedica Therapeutics Inc. (DMAC).

Signal8 holds 6 ownership filings by Krop Julie (1 Form 3, 5 Form 4), filed between Jun 12, 2025 and Jun 24, 2026. Those filings report 6 transactions, from Jun 11, 2025 to Jun 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Krop Julie's filings is in MINNEAPOLIS, MN.

Recent filings by Krop Julie

Jun 23, 2026: Option exercise of AQST shares (Form 4, code M).
Jun 23, 2026: Open-market sale of AQST shares (Form 4, code S).
Jun 10, 2026: Grant or award of AQST derivative securities (Form 4, code A).
Jun 1, 2026: Grant or award of DMAC derivative securities (Form 4, code A).
Aug 11, 2025: Grant or award of DMAC derivative securities (Form 4, code A).

Other insiders filing for Aquestive Therapeutics, Inc. (AQST)

Cochran John, Director
Barber Daniel, President and CEO
Daly Richard J, Director
Korczynski Sherry, Chief Commercial Officer
Boyd Peter E., Chief People Officer
Jung Cassie, Chief Operating Officer

How to read Form 4 transaction codes